Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etofylline nicotinate is a small molecule drug classified as a xanthine derivative and a theophylline analog. It acts primarily as a bronchodilator and vasodilator, used in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its mechanism of action involves inhibition of phosphodiesterase enzyme, leading to increased intracellular cyclic AMP (cAMP) levels, which results in relaxation of bronchial smooth muscle. Additionally, it may act as an adenosine receptor antagonist. Etofylline nicotinate may also exhibit anti-inflammatory effects by reducing airway inflammation and mucus production[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etofylline nicotinate.